Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Sci Rep ; 8(1): 14999, 2018 10 09.
Artículo en Inglés | MEDLINE | ID: mdl-30301959

RESUMEN

Cardiovascular diseases and thrombotic events became major clinical problems in the combined antiretroviral therapy (cART) era. Although the precise mechanisms behind these clinical problems have not been fully elucidated, a persistent pro-inflammatory state plays a central role. As platelets play important roles on both, thrombus formation and inflammatory/immune response, we aimed at investigating platelet function in HIV-infected subjects virologically controlled through cART. We evaluate parameters of activation, mitochondrial function and activation of apoptosis pathways in platelets from 30 HIV-infected individuals under stable cART and 36 healthy volunteers. Despite viral control achieved through cART, HIV-infected individuals exhibited increased platelet activation as indicated by P-selectin expression and platelet spreading when adhered on fibrinogen-coated surfaces. Platelets from HIV-infected subjects also exhibited mitochondrial dysfunction and activation of apoptosis pathways. Finally, thrombin stimuli induced lower levels of P-selectin translocation and RANTES secretion, but not TXA2 synthesis, in platelets from HIV-infected individuals compared to control; and labeling of platelet alpha granules showed reduced granule content in platelets from HIV-infected individuals when compared to healthy subjects. In summary, platelets derived from HIV-infected individuals under stable cART exhibit a phenotype of increased activation, activation of the intrinsic pathway of apoptosis and undermined granule secretion in response to thrombin.


Asunto(s)
Terapia Antirretroviral Altamente Activa/efectos adversos , Enfermedades Cardiovasculares/sangre , Infecciones por VIH/tratamiento farmacológico , Inflamación/sangre , Trombosis/sangre , Adulto , Apoptosis/efectos de los fármacos , Enfermedades Cardiovasculares/inducido químicamente , Enfermedades Cardiovasculares/genética , Enfermedades Cardiovasculares/patología , Quimiocina CCL5/genética , Femenino , VIH/patogenicidad , Infecciones por VIH/complicaciones , Infecciones por VIH/genética , Infecciones por VIH/virología , Voluntarios Sanos , Humanos , Inflamación/inducido químicamente , Inflamación/patología , Masculino , Mitocondrias/genética , Mitocondrias/patología , Monocitos , Selectina-P/genética , Activación Plaquetaria/efectos de los fármacos , Activación Plaquetaria/genética , Agregación Plaquetaria/efectos de los fármacos , Trombina/metabolismo , Trombosis/inducido químicamente , Trombosis/genética , Trombosis/virología
2.
BMC Infect Dis ; 16: 270, 2016 06 10.
Artículo en Inglés | MEDLINE | ID: mdl-27286652

RESUMEN

BACKGROUND: Tuberculosis is one of the leading causes of death from infectious diseases worldwide, mainly after the human immunodeficiency virus (HIV) epidemics. Patient with HIV-related illness are more likely to present with severe TB due to immunosuppression. Very few studies have explored HIV/TB co-infection in critically ill patients. The goal of this study was to analyze factors associated with long-term mortality in critically ill patient with HIV-related disease coinfected with TB. METHODS: We conducted a retrospective study in an infectious disease reference center in Brazil that included all patient with HIV-related illness admitted to the ICU with laboratory-confirmed tuberculosis from March 2007 until June 2012. Clinical and laboratory variables were analyzed based on six-month survival. RESULTS: Forty-four patients with HIV-related illness with a confirmed diagnosis of tuberculosis were analyzed. The six-month mortality was 52 % (23 patients). The main causes of admission were respiratory failure (41 %), severe sepsis/septic shock (32 %) and coma/torpor (14 %). The median time between HIV diagnosis and ICU admission was 5 (1-60) months, and 41 % of patients received their HIV infection diagnosis ≤ 30 days before admission. The median CD4 count was 72 (IQR: 23-136) cells/mm(3). The clinical presentation was pulmonary tuberculosis in 22 patients (50 %) and disseminated TB in 20 patients (45.5 %). No aspect of TB diagnosis or treatment was different between survivors and nonsurvivors. Neurological dysfunction was more prevalent among nonsurvivors (43 % vs. 14 %, p = 0.04). The nadir CD4 cell count lower than 50 cells/mm(3) was independently associated with Six-month mortality (hazard ratio 4.58 [1.64-12.74], p < 0.01), while HIV diagnosis less than three months after positive serology was protective (hazard ratio 0.27, CI 95 % [0.10-0.72], p = 0.01). CONCLUSION: The Six-month mortality of HIV critically ill patients with TB coinfection is high and strongly associated with the nadir CD4 cell count less than 50 cels/mm(3).


Asunto(s)
Coinfección/mortalidad , Enfermedad Crítica/mortalidad , Infecciones por VIH/mortalidad , Insuficiencia Respiratoria/mortalidad , Sepsis/mortalidad , Tuberculosis Pulmonar/mortalidad , Adulto , Brasil/epidemiología , Recuento de Linfocito CD4 , Coinfección/epidemiología , Comorbilidad , Enfermedad Crítica/epidemiología , Femenino , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Infecciones por VIH/inmunología , Hospitalización , Humanos , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Mortalidad , Puntuaciones en la Disfunción de Órganos , Modelos de Riesgos Proporcionales , Insuficiencia Respiratoria/epidemiología , Estudios Retrospectivos , Factores de Riesgo , Sepsis/epidemiología , Factores de Tiempo , Tuberculosis/mortalidad , Tuberculosis Pulmonar/epidemiología , Adulto Joven
3.
PLoS One ; 8(7): e68730, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23874739

RESUMEN

INTRODUCTION: In recent years, the incidence of sepsis has increased in critically ill HIV/AIDS patients, and the presence of severe sepsis emerged as a major determinant of outcomes in this population. The inflammatory response and deregulated cytokine production play key roles in the pathophysiology of sepsis; however, these mechanisms have not been fully characterized in HIV/AIDS septic patients. METHODS: We conducted a prospective cohort study that included HIV/AIDS and non-HIV patients with septic shock. We measured clinical parameters and biomarkers (C-reactive protein and cytokine levels) on the first day of septic shock and compared these parameters between HIV/AIDS and non-HIV patients. RESULTS: We included 30 HIV/AIDS septic shock patients and 30 non-HIV septic shock patients. The HIV/AIDS patients presented low CD4 cell counts (72 [7-268] cells/mm(3)), and 17 (57%) patients were on HAART before hospital admission. Both groups were similar according to the acute severity scores and hospital mortality. The IL-6, IL-10 and G-CSF levels were associated with hospital mortality in the HIV/AIDS septic group; however, the CRP levels and the surrogates of innate immune activation (cytokines) were similar among HIV/AIDS and non-HIV septic patients. Age (odds ratio 1.05, CI 95% 1.02-1.09, p=0.002) and the IL-6 levels (odds ratio 1.00, CI 95% 1.00-1.01, p=0.05) were independent risk factors for hospital mortality. CONCLUSIONS: IL-6, IL-10 and G-CSF are biomarkers that can be used to predict prognosis and outcomes in HIV/AIDS septic patients. Although HIV/AIDS patients are immunocompromised, an innate immune response can be activated in these patients, which is similar to that in the non-HIV septic population. In addition, age and the IL-6 levels are independent risk factors for hospital mortality irrespective of HIV/AIDS disease.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/inmunología , Infecciones por VIH/inmunología , Sepsis/inmunología , Choque Séptico/inmunología , Adulto , Anciano , Anciano de 80 o más Años , Biomarcadores/metabolismo , Proteína C-Reactiva/inmunología , Proteína C-Reactiva/metabolismo , Recuento de Linfocito CD4/métodos , Estudios de Cohortes , Enfermedad Crítica , Citocinas/inmunología , Citocinas/metabolismo , Femenino , Factor Estimulante de Colonias de Granulocitos/inmunología , Factor Estimulante de Colonias de Granulocitos/metabolismo , Mortalidad Hospitalaria , Humanos , Inmunidad Innata , Interleucina-10/inmunología , Interleucina-10/metabolismo , Interleucina-6/inmunología , Interleucina-6/metabolismo , Masculino , Persona de Mediana Edad , Estudios Prospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...